Eribulin plus pyrotinib In trastuzumab-resistant HER2-positive advanced breast cancer: A single-arm, multicenter phase II trial (EPIC trial). Association of pre-treatment HER2 amplicon mRNA signature, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback